# TroFuse-033 (NCT06952504)

> A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

No report yet. It can be ordered.

- Drugs tested: sacituzumab tirumotecan plus pembrolizumab
- Indication: mismatch repair-proficient endometrial cancer, first-line maintenance

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06952504
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Endometrial Cancer
- Interventions: Pembrolizumab; Carboplatin; Paclitaxel; Docetaxel; Sacituzumab Tirumotecan; Cisplatin
- Enrollment: 1123
- Primary outcome: Maintenance Treatment: Progression-Free Survival (PFS)
- Primary outcome: Maintenance Treatment: Overall Survival (OS)

## Indexed commentary on TroFuse-033 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 8 YouTube videos
- 3 podcast episodes
- 1 post on X

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=trofuse-033-nct06952504

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06952504", "email": "<work email>"}; the inbox owner confirms by the emailed link.